SNTI - Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting | Benzinga
– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics –
– Two poster presentations showcasing Senti Bio's proprietary Gene Circuit platform –
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 1-5, 2023, in San Diego, CA.
"This continues to be a definitive year for Senti with multiple presentations across multiple medical and scientific venues," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "The four posters at this year's SITC meeting highlight the breadth and modularity of our platform. We also continue to make progress with our longstanding partner BlueRock, as highlighted by our two joint posters. Overall, I am pleased with the growing interest in our Gene Circuit platform throughout the global scientific community as we soon embark on using these technologies in the clinic."
The presentations and posters can be accessed on the Scientific Presentations & Publications section of the Senti Bio website.
PRESENTATIONS HIGHLIGHTS
NOT gate gene circuits expand the range of tumor-associated antigens addressable by CAR-NK and -T cell therapies
In collaboration with GeneFab LLC
Abstract number: 257
Location: Poster Halls A and B1
Date and time: November 3, 2023, 9:00 am - 7:00 pm PT
- Many tumor-associated antigens are also expressed on healthy cells, risking on-target/off-tumor toxicity.
- Senti's Bio proprietary Logic Gating can help design cell therapies that address more tumor types by increasing the therapeutic window.
- The Company's NOT Gate technology, which is used in SENTI-202, aims to protect healthy cells in vitro and in vivo without interfering with anti-cancer killing in both T cells and NK cells.
Small-molecule regulated safety switch for improved safety of CAR cell therapies in the brain
In collaboration with BlueRock Therapeutics and GeneFab LLC
Abstract number: 24
Location: Poster Halls A and B1
Date and time: November 4, 2023, 9:00 am - 8:30 pm PT
- Optimization of tamoxifen-responsive binding domains by computational design followed by high throughput screening yielded safety switches that trigger cell death via tamoxifen metabolites.
- Tamoxifen-regulated safety switch achieves complete killing at pharmacologically relevant concentrations in primary T cells within 48 hours of induction, enabling potential use in cell therapies for enhanced safety.
Smart sensor promoters drive state-specific gene circuits to convert immunosuppressive macrophages into an anti-tumor phenotype
In collaboration with BlueRock Therapeutics and GeneFab LLC
Abstract number: 430
Location: Poster Halls A and B1
Date and time: November 4, 2023, 9:00 am - 8:30 pm PT
- Putative native enhancers mined from ATAC-Seq can be engineered into strong and M2c polarization state selective ...